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Human, rat, and mouse kidney cells express functional
erythropoietin receptors
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Cells of human, rat, and mouse kidney express functional eryth- the liver [1–5]. Renal EPO is first secreted into peritubu-
ropoietin receptors. lar capillary blood that also contains residual EPO [1,
Background. Erythropoietin (EPO), secreted by fibroblast- 6]. From here, renal veins deliver the hormone into thelike cells in the renal interstitium, controls erythropoiesis by
systemic circulation [1, 6].regulating the survival, proliferation, and differentiation of ery-
Intriguingly, EPO-producing cells are also in directthroid progenitor cells. We examined whether renal cells that
are exposed to EPO express EPO receptors (EPO-R) through contact with the basal aspects of proximal and distal
which analogous cytokine responses might be elicited. tubular cells [1–5, 7]. We reasoned that this anatomical
Methods. Normal human and rat kidney tissue and defined relationship between EPO-secreting cells, the intrarenalcell lines of human, rat, and mouse kidney were screened, using
capillary network, and tubular and other renal cells couldreverse transcription-polymerase chain reaction, nucleotide se-
facilitate endocrine and paracrine actions of EPO withinquencing, ligand binding, and Western blotting, for the expres-
sion of EPO-R. EPO’s effects on DNA synthesis and cell prolif- the kidney itself. This would require that potential tar-
eration were also examined. gets, such as renal tubular cells, possess functional EPO
Results. EPO-R transcripts were readily detected in cortex,
receptors (EPO-Rs) on their surface [8]. This has, how-medulla, and papilla of human and rat kidney, in mesangial
ever, not been systematically investigated to date, and(human, rat), proximal tubular (human, mouse), and medullary
collecting duct cells (human). Nucleotide sequences of EPO-R as a consequence, endocrine or paracrine actions of EPO
cDNAs from renal cells were identical to those of erythroid within the kidney have not been considered. This is
precursor cells. Specific 125I-EPO binding revealed a single class primarily due to the assumption, until recently, that
of high- to intermediate-affinity EPO-Rs in each tested cell
EPO-Rs existed only on erythroid progenitor cells andline (kD 96 pm to 1.4 nm; Bmax 0.3 to 7.0 fmol/mg protein).
that, therefore, EPO’s effects were restricted to theseWestern blots of murine proximal tubular cell membranes re-
vealed an EPO-R protein of approximately 68 kDa. EPO stim- cells [8].
ulated DNA synthesis and cell proliferation dose dependently. Recently, however, Anagnostou et al showed that vas-
Conclusion. This is the first direct demonstration, to our cular endothelial cells possess EPO-Rs and proliferateknowledge, that renal cells possess EPO-Rs through which
and migrate in response to EPO [9, 10]. Others haveEPO stimulates mitogenesis. This suggests currently unrecog-
demonstrated that EPO-Rs are present in rodent pla-nized cytokine functions for EPO in the kidney, which may
prove beneficial in the repair of an injured kidney while being centa [11], rat brain and neuronal PC12 and SN6 cells
potentially detrimental in renal malignancies. [12, 13], testicular Leydig cells [14], and gastric epithelial
cells [15]. In Leydig cells, EPO stimulates testosterone
synthesis, and in gastric mucosal cells, it stimulates mito-
Erythropoietin (EPO) is a 34 kDa glycoprotein hor- genesis. In the brain of gerbils, EPO was shown to ame-
mone that controls erythropoiesis by receptor-mediated liorate the injury caused by ischemia [16], whereas in
regulation of survival, proliferation, and differentiation glomerular mesangial cells, it was found to activate cal-
of erythroid progenitor cells [1]. In the adult, EPO is cium channels, potentially resulting in cellular contrac-
secreted primarily by fibroblast-like interstitial cells of tion [17]. Taken together, these observations provide
the renal cortical labyrinth and, to a smaller degree, by growing evidence in support of the notion that EPO
may possess important physiological functions in various
nonhemopoietic cells.Key words: EPO, mitogenesis, erythropoiesis, injury repair, renal ma-
lignancies. To explore EPO’s nonhemopoietic functions further,
we conducted a systematic search for EPO-R in humanReceived for publication June 23, 1998
and rat kidney tissue and in various lines of culturedand in revised form September 15, 1998
Accepted for publication September 22, 1998 renal cells. We detected authentic EPO-R transcript and
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surface receptors. Receptor activation stimulated mito-
genesis in vitro, demonstrating that EPO may act through
its receptors in the kidney as a currently unrecognized
cytokine.
Fig. 1. Schema of the mRNA that encodes the erythropoietin receptor
METHODS [24, 25]. It is composed of eight exons; exons I through V represent the
exoplasmic domain (N-terminus), exon VI, the single transmembraneHuman kidney domain, and exons VII and VIII, the cytoplasmic domain (C-terminus).
Regions of the human EPO-R transcript that are bound by the threeNormal tissue from two different nephrectomy speci-
PCR primers (1 through 3) are shown above, and PCR primers (1 andmens was obtained with our Institutional Review Board 2) utilized for rat and mouse EPO-R transcripts, below the diagram
(IRB) approval. Tissues were immediately placed into (not to scale).
chilled phosphate-buffered saline (PBS), rinsed free of
blood, frozen in liquid nitrogen, and dissected into cor-
tex, outer medulla, and papilla. The samples were stored
factor (10 ng/ml), T3 (4 pg/ml), and 10% newborn calfat 2708C until RNA was extracted. mRNA from normal
serum (NCS; Hyclone, Logan, UT, USA) at 378C in 5%human fetal liver (week 19) served as a positive control.
CO2/air [19]. Defined, normal mesangial cells obtained
Rat kidney from adult human (HMCs) and rat (RMCs) kidney at
passages 2 to 3 were grown to high subconfluence inFor all studies (approved by the Institutional Animal
DMEM with 10% NCS at 378C in 5% CO2/air. Trans-Care and Use Committee), normal, adult, male Sprague-
formed murine proximal tubular cells (MCTs) are a well-Dawley rats weighing 300 to 350 g were used. Animals
defined cell line that retains many characteristics of na-had free access to food and water. Before sacrifice, rats
tive proximal tubular cells [20]. They were grown inwere anesthetized (ketamine, 1 mg, and acepromazine,
DMEM with 10% NCS at 378C in 5% CO2/air. A human0.1 mg/100 g body wt i.p.), and hearts and kidneys were
erythroleukemia cell line that expresses high numbersrapidly removed, placed in chilled PBS, rinsed free of
of EPO-Rs, OCIM 1 cells [21], served as positive con-blood, frozen in liquid nitrogen, and stored at 2708C
trols. They were grown at 378C in 5% CO2/air in suspen-until RNA was extracted. Kidneys were dissected into
sion culture, using Iscove’s modified Dulbecco’s media,cortex, outer medulla, and papilla.
containing 10% heat-inactivated fetal calf serum (FCS)Because anemia causes the accumulation of
and 5 3 1025 m b-mercaptoethanol. HeLa cells (ATTC,EPO-R–expressing erythroid progenitor cells, it was
Rockville, MD, USA) served as negative human con-used to obtain negative and positive controls [8]. Accord-
trols. They were grown in MEM and 10% NCS. HCDingly, using a modification of a previously reported
57, an EPO-dependent murine erythroleukemia cell linemethod [18], adult male Balb C mice (N 5 3), weighing
with high level expression of EPO-Rs [22], served as the40 to 50 g, were made anemic with a 5 mg/ml solution
positive control. They were grown in suspension cultureof phenylhydrazine in PBS administered once a day for
media as described for OCIM 1 cells. In addition, 1three days (50 mg/kg body wt i.p.). Sham animals (N 5
U/ml of human EPO was added to the culture media.3) were treated with an equal volume of PBS. After two
Mouse NIH 3T3 cells, embryonic mouse fibroblasts,additional days, hematocrits in phenylhydrazine-treated
served as negative controls (ATTC). They were grownanimals had decreased from 46 6 2% to 31 6 3% (P ,
in DMEM with 10% NCS at 378C in 5% CO2/air.0.05), whereas they remained stable in sham animals
(45 6 2% and 46 6 2%). Animals were then sacrificed
mRNA isolation, RT-PCR, and gel electrophoresisunder nembutal anesthesia (40 mg/kg body wt i.p.), and
Total RNA was isolated from tissues and cultured cellsspleens were harvested, immediately frozen in liquid ni-
by an acid guanidinium-thiocyanate-phenol-chloroformtrogen, and stored at 2708C. Subsequently, RNA was
method [23], using TRI Reagent (Molecular Researchextracted, and cell membranes were prepared for West-
Center, Inc., Cincinnati, OH, USA). For the reverse tran-ern blotting, as described later here.
scription-polymerase chain reactions (RT-PCR) 1 mg of
Cell lines total mRNA was reverse transcribed (M-MLV reverse
transcriptase; GIBCO, Grand Island, NY, USA), andDefined, normal human proximal tubular cells (HCTs;
the resulting cDNAs were subjected to 35 cycles of theClonetics Corp., San Diego, CA, USA) at passage 2 and
PCR. The amplification of the examined cDNAs wasnormal human medullary collecting duct cells (HMCDs)
linear up to 40 PCR cycles for all primer sets used inat passages 2 and 3 were grown to high subconfluence
this study. For human samples, three sets of PCR primersin a 1:1 mixture of Dulbecco’s modified Eagle’s medium
were chosen, each specific to a different domain of hu-(DMEM) and F12 containing 1 3 insulin, transferrin,
selenium (Sigma, St. Louis, MO, USA), epithelial growth man EPO-R cDNA (Fig. 1). Their individual sequences
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and respective positions within the coding sequence are and second EPO-R primer sets (Fig. 1) from HCT and
MCT mRNAs were subcloned (pCR 3.1 vector; Originalas follows [24]: (1) sense, 59-CCTGGTCGGAGCCTGT
TA Cloning Kit; Invitrogen, San Diego, CA, USA). TheGT-39, antisense, 59-CACGACGACTGGCACGAG-39,
obtained subclones then underwent automated fluores-yielding a 104 bp PCR product of nucleotides 704–807
cent DNA sequencing at the University of Utah Corelocated on exons V and VI, spanning extracellular and
Sequencing Facility.transmembrane domains; (2) sense, 59-TCGTGGTCAT
CCTGGTGCTGCTGA-39, antisense, 59-ACCTTCAG
Erythropoietin binding to cellsGAGAGTCTCGCGACGA-39, yielding a 240 bp PCR
Cells were grown to subconfluence, as described ear-product of nucleotides 776–1015, located on exons VI
lier here, and were mechanically harvested. They wereand VIII, representing transmembrane and cytoplasmic
then washed at 48C for three minutes with 0.5 m NaCldomains; and (3) sense, 59-CCCGAGCCCAGAGAGC
and 0.25 m acetic acid (pH 2.5) in order to remove EPOGAGTT-39, antisense, 59-TAGGAGGACGAGTAGA
bound to the cell surface [12] and were washed twiceCGAAA-39, yielding a 372 bp PCR product of nucleo-
more with PBS (pH 7.3). Binding assays were carried outtides 885–1229 on exons VII and VIII, representing cyto-
by placing approximately 1 3 106 cells in an incubationplasmic domains of the human EPO-R.
mixture, containing PBS with 0.1% bovine serum albumin,For rat and mouse EPO-R cDNAs, two sets of primers
0.1% NaN3, to inhibit internalization, and a 200-fold excesswere used for PCR amplification of homologous se-
of recombinant human erythropoietin (rHuEPO) in a to-quences (Fig. 1) [12, 25]: (1) sense, 59-TCTGGGAGGC
tal volume of 170 ml. 125I-rHuEPO (specific activity 948GGCGAACT-39, antisense, 59-GAGGAGCGATGGTG
Ci/mmol; Amersham, Arlington Heights, IL, USA) wasGCGTAGT-39, yielding a 219 bp PCR product of nucleo-
added to cell aliquots in increasing concentrations (40tides 188–406 on exons II and III, representing an extra-
to 620 pm) and was incubated for three hours at 158C.cellular domain; and (2) sense, 59-CGCTGTCTCTCAT
The cells were then pelleted and washed three timesTCTCGTC-39, antisense, 59-GGTTCGGGTCTCTTAC
with 200 ml of ice-cold PBS, and cell-associated radioac-TCAA-39, yielding a 118 bp PCR product of nucleotides
tivity was measured with a gamma counter. By measuring758–875 on exons VI and VII, representing transmem-
the difference in radioactivity when cells were incubatedbrane to cytoplasmic domains of the rat/mouse EPO-R.
either in the presence or in the absence of 200-fold excessAll primer pairs were chosen to span introns (Fig. 1),
unlabeled EPO (recombinant human EPO; Amgen,thus facilitating control for contamination by genomic
Royal Oaks, CA, USA), the amount of specific EPODNA. All cell and tissue extracts were subjected to the
binding was determined. Assay conditions were designed
PCR reaction once with and once without an initial re- to keep total EPO binding (specific plus nonspecific)
verse transcription. below 10% of the total amount of radioligand added.
As internal controls, human and mouse/rat b-actin To obtain Kd and Bmax, both linear Scatchard [26] andmRNAs were simultaneously reverse transcribed and nonlinear (GraphPad Software, Inc., San Diego, CA,
PCR amplified. The primers used for human b-actin USA) regression analyses of the equilibrium-binding
cDNA had the following sequence: sense, 59-TGTCC data were performed. The time course of ligand binding
ACCTTCCAGCAGATGT-39, antisense, 59-CACCTT was determined by incubating 125I-rHuEPO at a concen-
CACCGTTCCAGTTTT-39, yielding a 249 bp product. tration of 620 pm with approximately 1 3 106 cells at 158C
The primers used for rat/mouse b-actin cDNA had the for four hours. To test whether specific EPO binding
following sequence: sense, 59-AGAGGGAAATCGTG has a linear correlation with the number of cells used,
CGTGACA-39, antisense, 59-CACTGTGTTGGCATA increasing numbers of cells, from 0 to 9 3 106, were
GAGGTC-39, yielding a 279 bp product. incubated with 125I-rHuEPO (620 pm) for three hours at
All PCR products were size fractionated on 2.5% Nu- 158C both in the absence and the presence of 200-fold
Sieve agarose and 1% agarose gel (FMC Bioproducts, excess unlabeled EPO.
Rockland, ME, USA), stained with ethidium bromide,
Immunological detection of erythropoietinand band locations were recorded by photographing
receptor proteinthem under ultraviolet light. Size standards of DNA were
run in parallel (pBR322 DNA MSP I digest; New En- Murine proximal tubular cells (approximately 5 3 106),
gland Biolabs, Beverly, MA, USA). grown in 75 cm2 flasks, were washed twice with ice-cold
PBS and were collected by scraping and centrifuging.
Nucleotide sequencing The pellet was frozen at 2708C. Spleens from anemic
Besides the use of appropriate negative and positive and sham mice were obtained, rinsed free of blood, and
controls, unequivocal proof for the authenticity of renal frozen at 2708C. Cell membranes from MCTs and
EPO-R transcripts was obtained by subcloning and se- spleens were prepared as previously reported [17]. In
quencing of the respective PCR products. Accordingly, brief, approximately 50 mg of spleen tissue or 5 3 106
MCTs were homogenized in a polytron in 1 ml hypotonicPCR products generated with the species-specific first
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buffer (50 mm Tris-HCl, pH 7.4, 2 mm Na3VO4, 50 mm ing the cells for 20 additional hours with varying concen-
trations of EPO or 10% NCS. The cells were then pulsedNaF, 10 mm Na2P2O7, 1 mm phenylmethylsulfonyl fluo-
with 0.5 mCi [3H]-thymidine (specific activity 70 to 90ride) and incubated for 30 minutes at 48C. The sample
Ci/mmol; New England Nuclear, Boston, MA, USA)was centrifuged at 48C for 20 minutes at 6000 3 g. Mem-
and incubated for four more hours before being washedbrane proteins in the pellet were extracted over 60 min-
with 750 ml cold PBS and again with cold 5% trichloro-utes at 48C with lysis buffer (PBS containing 5 mm ethyl-
acetic acid. Next, 750 ml of 0.25 m NaOH in 0.1% sodiumenediaminetetraacetic acid, pH 7.4, 1% Triton X-100,
dodecyl sulfate were added for 30 minutes in order to0.5 mm phenylmethylsulfonyl fluoride). Following cen-
solubilize proteins. Radioactivity was determined bytrifugation for 20 minutes at 6000 3 g at 48C, the superna-
scintillation counting, with counts expressed as cpm pertant, containing cell membrane protein, was collected.
microgram of protein. Protein was measured by the BCAThese cell membrane protein preparations from
Protein Assay (Pierce, Rockford, IL, USA).spleens and MCTs were then immunoprecipitated by
adding 10 ml of an affinity-purified antibody directed
Cell proliferationagainst the C-terminus of the murine EPO-R (Santa
All tested cells were seeded at 1 3 104 per well in 96-Cruz Biotechnology, Santa Cruz, CA, USA). This mix-
well plates and allowed to attach overnight in appro-ture was incubated overnight at 48C. Protein A/G Plus-
priate serum-containing media. Cells were made quies-Agarose (Santa Cruz Biotechnology) was then added,
cent by incubation in serum-free media for 24 hours.and the mixture was incubated for another three hours
Newborn calf serum (10%) or EPO, at incremental con-at 48C. After four washes in lysis buffer, the pelleted
centrations, was then added, and the incubation was con-agarose antibody complex was suspended in 40 ml 2 3
tinued for 48 hours. At this time, media were removedLaemmli’s sample buffer and heated at 1008C for four
and replaced with fresh media (without phenol red andminutes prior to electrophoresis on 9% sodium dodecyl
serum) containing 5 mg/ml MTT [3-(4,5-dimethylthiazol-sulfate-polyacrylamide gel, as previously reported [27,
2-yl)-2,5-diphenyltetrazolium bromide; Thiazolyl blue;28]. The separated protein bands were then electropho-
Sigma] and cells were incubated at 378C for an additionalretically transferred to Hybond-P membrane (Amer-
three hours. After this, the media were removed, andsham). These were incubated for two hours at room
100 ml of 0.04 n HCl in isopropanol were added to eachtemperature in a mixture of blocking buffer (TBS-T: 10
well in order to solubilize the blue MTT reduction prod-mm Tris-buffered saline, pH 8.0, 0.1% Tween 20) and
uct formed in viable cells. The absorbance was read on5% nonfat powdered milk in order to prevent binding
a microplate reader at 570 nm with background subtrac-
to nonspecific sites. A 1:1000 dilution of the primary tion at 650 nm. Media d-glucose concentration at the
antibody in blocking buffer was then added to the mem- time of the MTT assay was well maintained, thus pre-
branes, and they were incubated at room temperature venting an underestimation of cell numbers [29]. In addi-
for 45 minutes. After three washes in TBS-T, the second tion, cell proliferation was assessed by hemocytometer
antibody was added (1:1000 dilution of a horseradish counting of trypsinized cells. There was an excellent lin-
peroxidase-conjugated antirabbit IgG), followed by a ear correlation (r 5 0.99) between cell counts and results
one-hour incubation at room temperature. After four obtained by the MTT assay.
washes in TBS-T, the protein bands were made visible,
using a chemiluminescence detection system (ECL, Am- Data reporting and statistical analysis
ersham) and recorded on radiographic film as previously All data on rat and human tissues and individual cell
reported [27]. lines are representative of at least three to six replications
The specificity of anti-EPO-R antibody binding by or independent experiments, respectively. Data are re-
MCT protein extracts was further assessed by reacting ported as means 6 se. Differences between data means
the primary blots, prepared as described earlier here, were analyzed for statistical significance (P , 0.05) using
with a 1:1000 dilution of primary antibody that had been Student’s t-test for paired and independent populations,
neutralized (17 hours at 48C) with a 10-fold (by mass) as well as analysis of variance [30]. Apparent Kd and
excess of EPO-R antigen (C-terminal peptide; Santa Bmax values for 125I-EPO binding were derived by both
Cruz Biotechnology). The remaining steps of the immu- linear Scatchard [26] and nonlinear (GraphPad Software)
nodetection protocol were then performed as described regression analyses of the equilibrium-binding data.
earlier here.
RESULTSDNA synthesis
Erythropoietin receptor transcripts in human andCells were grown in 24-well plates. Once attached and
rat kidneysubconfluent, the cells were serum deprived for 24 hours.
The effect of EPO on DNA synthesis, determined by Figure 2 shows ethidium bromide-stained agarose gels
of EPO-R PCR products obtained from normal human[3H]-thymidine incorporation, was assessed by incubat-
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Fig. 2. Erythropoietin receptor (EPO-R)
transcripts in human and rat kidney. (A)
Ethidium bromide-stained gel shows the ex-
pected 104 bp EPO-R PCR products (first
primer set in Fig. 1) from human renal cortex
(lane 5), medulla (lane 6), and papilla (lane
7). The first lane shows a DNA ladder. Lanes
2 through 4 show the corresponding 249 bp
b-actin PCR products, and lane 8 demon-
strates that deletion of the RT reaction pre-
vents subsequent formation of PCR products
(tested on papilla, lane 7). (B) Ethidium bro-
mide-stained gel shows the expected 118 bp
EPO-R PCR products (first primer set in Fig.
1) from rat renal cortex (lane 5), medulla (lane
6), and papilla (lane 7). Other lane explana-
tions as in (A).
(Fig. 2A) and rat (Fig. 2B) kidney. The bands in lanes yielded PCR products of predicted sizes (118 and 219 bp
for EPO-R; 279 bp for b-actin), whereas rat myocardium5 (cortex), 6 (medulla), and 7 (papilla) of Figure 2A
represent the expected 104 bp PCR products of the hu- showed no EPO-R message (Fig. 3C).
man EPO-R cDNA. The first lane shows DNA size stan-
Erythropoietin receptor transcripts in renal cellsdards, and lane 8 demonstrates that deletion of the re-
verse transcription step yields no detectable PCR Because the renal circulation may contain erythroid
progenitor cells that express EPO-Rs and because theproduct in papillary tissue (lane 7). The bands in lanes
2 through 4 represent the 249 bp b-actin PCR products kidney is composed of vascular, interstitial, glomerular,
and distinct tubular cells, we next screened for the pres-from cortex, medulla, and papilla, respectively. Bands
of comparable intensity were obtained with the other ence of EPO-R message in defined renal cell lines grown
in culture. Figure 4A shows the data from HCTs andtwo primer sets, yielding expected PCR products of 240
bp and 372 bp. Human fetal liver served as the positive HMCs. Bands in lanes 4, 6, and 8 depict the expected
104, 240, and 372 bp products of the human EPO-R incontrol; it yielded identical PCR products (104, 240, and
372 bp) as shown in Figure 3A. HCT cells. Bands in lanes 5, 7, and 9 show the corre-
sponding signals from HMCs. In lane 1 DNA size stan-Figure 2B depicts, in lanes 5 (cortex), 6 (medulla), and
7 (papilla), the expected 118 bp PCR products of the rat dards and in lanes 2 and 3, the respective 249 bp b-actin
signals are depicted. Figure 4B shows the data fromEPO-R cDNA, and lanes 2 through 4 show the corre-
sponding 279 bp b-actin PCR product from renal cortex, HMCDs. Lane 2 shows the b-actin signal, and lanes 3
through 6 show the EPO-R PCR products of expectedmedulla, and papilla, respectively. The first lane shows
DNA size standards, and lane 8 demonstrates that dele- sizes (372 bp, 240 bp, and 104 bp). Figure 5A confirms
that EPO-R transcripts from human erythroleukemiation of the reverse transcription step yields no detectable
PCR product in papillary tissue (lane 7). Bands of similar cells (OCIM 1) are comparable to those obtained in renal
cells (positive control: bands in lanes 3, 4, and 5 representintensity were obtained with the other primer set, yield-
ing the expected PCR product of 219 bp. Spleen from EPO-R PCR products, lane 1 DNA size standards, and
lane 2 b-actin signal, respectively), whereas no such mes-anemic mice served as positive control (Fig. 3B); it
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EPO-R message is detected in NIH 3T3 cells (negative
control: lanes 6 and 7 correspond to lanes 3 and 4, and
lane 5 represents b-actin). Collectively, these data dem-
onstrate that murine proximal tubular and rat glomerular
mesangial cells express EPO-R mRNA.
Sequencing of EPO-R cDNA
To directly show that the PCR products derived from
renal cells represent authentic EPO-R message, gener-
ated cDNAs were subcloned, and their sequences were
analyzed. Thus, sequencing of EPO-R cDNAs generated
from HCT mRNA, using both set 1 (104 bp, exons V
and VI) and set 2 (240 bp, exons VII and VIII) of PCR
primers (Fig. 1; Methods section), yielded results identi-
cal to published EPO-R DNA sequences [19]. The se-
quences of cDNAs generated from MCTs and rat kidney
cortex by set 1 (219 bp, exons II and III; Fig. 1; Methods
section) and set 2 (118 bp) of primer pairs specific to rat/
mouse EPO-R were also identical to published EPO-R
DNA sequences [20]. These data prove unequivocally
that HCTs and MCTs as well as rat kidney cortex express
authentic EPO-R transcripts.
Specific erythropoietin binding to cell surface and
immunologic detection of erythropoietin
receptor protein
In MCTs and HCTs, and in HMCDs, specific binding
of 125I-EPO to cell surface EPO-R was examined. FigureFig. 3. EPO-R transcripts in human, mouse, and rat control tissues.
(A) Fetal human liver served as a positive control. Gel shows the EPO-R 6A shows equilibrium binding data in MCTs. Specific
PCR products obtained with the three primer sets (Fig. 1): 372 bp (lane
binding of 125I-EPO in these cells occurred to a single3), 104 bp (lane 4) and 240 bp (lane 5). Lane 1 depicts a DNA ladder
and lane 2 the 249 bp b-actin signal. (B) Anemic mouse spleen (positive class of high-affinity receptors (Kd 96.1 6 6.1 pm; Bmax
control). Gel shows the EPO-R PCR products obtained with the two 0.3 6 0.07 fmol/mg protein; N 5 3), and binding became
mouse/rat primer sets (Fig. 1): 219 bp (lane 3) and 118 bp (lane 4).
saturated over time (Fig. 6B). Nonlinear and ScatchardLane 1 depicts a DNA ladder, and lane 2 shows the 279 bp b-actin
signal. (C) Rat myocardium (negative control). EPO-R expression (219 analyses yielded comparable results. There was excellent
bp PCR product) was not detected (lane 3). Lane 1 depicts a DNA linear correlation (r 5 0.99) between specific ligand bind-
ladder and lane 2 the 279 bp b-actin signal.
ing in tested cell lines and cell numbers. The apparent
Kd in HCT cells was 1.1 6 0.1 nm and Bmax 1.6 6 0.2
fmol/mg (N 5 3), and in HMCDs (N 5 3) the apparent
Kd was 1.3 6 0.2 nm and Bmax 7.0 6 0.8 fmol/mg protein.sage is detected in HeLa cells (negative control: lane 7
Western blots for EPO-R protein (Fig. 7) were gener-shows no 372 bp EPO-R PCR product; lane 6 is the
ated after initial immunoprecipitation of MCT andb-actin signal). Together, these data demonstrate that
mouse spleen cell membrane protein with anti-EPO-RHCTs, collecting duct, as well as glomerular mesangial
antibody. Lane 1 on Figure 7A shows a representativecells express EPO-R mRNA.
Western blot from MCTs. Two immunoreactive proteinFigure 4C depicts corresponding data from MCTs and
bands of approximate molecular mass of 68 and 90 kDa,RMCs. Bands in lanes 4 and 6 represent the expected
respectively, are identified. When anti-EPO-R antibod-118 bp and 219 bp PCR products of the mouse EPO-R
ies were first neutralized with an excess of specific antigenin MCTs. Bands in lanes 5 and 7 represent those from
(C-terminal EPO-R peptide; Methods section), no EPO-RMCs. Bands in lanes 2 and 3 represent the respective
R–specific immunoreactivity was detected (lane 2). Lane279 b-actin signals, and lane 1 shows DNA size standards.
3 shows molecular weight standards. These data implyFigure 5B confirms that EPO-R transcripts from murine
that the detected bands possess EPO-R–specific antige-erythroleukemia cells (HCD 57, positive control) are com-
nicity. As positive control, spleen cell membrane pro-parable to those obtained in renal cells. Lanes 3 and 4
teins from anemic mice were utilized. In these, immuno-show 118 bp and 219 bp EPO-R PCR products, lane 1
DNA size standards, lane 2 b-actin signal), whereas no reactive protein bands of comparable molecular mass
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Fig. 4. EPO-R transcripts in renal cells. (A)
Human proximal tubular and mesangial cells.
Gel shows in lanes 4, 6, and 8 the expected
104, 240, and 372 bp PCR products of the
human EPO-R in proximal tubular cells
(HCT), and in lanes 5 and 9 those in mesangial
cells (HMC). The first lane shows a DNA lad-
der, lanes 2 and 3, the 249 bp b-actin signals
from HCT and HMC, respectively. (B) Hu-
man medullary collecting duct cells. Gel shows
all three EPO-R PCR products (lanes 3
through 5, 372, 104, 240 bp), a DNA ladder
(lane 1) and b-actin signal (lane 2). (C) Mouse
proximal tubular and rat mesangial cells.
Lanes 4 and 6 depict the expected 118 and
219 bp PCR products of the EPO-R in murine
proximal tubular (MCTs), and lanes 5 and 7
those in at mesangial cells (RMCs), respec-
tively. Lane 1 shows a DNA ladder and lanes
2 and 3 the corresponding 279 bp b-actin sig-
nals for each cell line.
(68 and 90 kDa) were identified (lane 2 on Fig. 7B); DISCUSSION
however, the 68 kDa protein was not detected in normal The unique anatomical relationship between EPO-
spleen (lane 1), whereas the 90 kDa band was detectable producing interstitial fibroblasts and adjacent tubular
both in normal and anemic spleens (lanes 1 and 2). This cells [1, 6] prompted us to ask whether renal cells possess
pattern suggests that the 68 kDa protein likely represents biologically active EPO-Rs that would enable them to
the EPO-R, because anemia stimulates the accumulation respond to EPO. In our examination of human and rat
of erythroid progenitor cells in the spleen, that is, cells kidney as well as various renal cell lines, we detected
that express the EPO-R [8]. Lane 3 shows molecular authentic, species-specific EPO-R expression at both the
weight standards. transcriptional and the translational level, a single class
of moderate- to high-affinity EPO-Rs, and specific, dose-
Mitogenic action of erythropoietin in MCTs dependent, mitogenic activity of EPO in vitro. These
Figure 8A shows that EPO dose dependently stimu- findings, when considered as a whole, make this the first
lates DNA synthesis in MCTs. Figure 8B shows that study, to our knowledge, to demonstrate conclusively
48 hours after EPO was added, MCT proliferation was that renal cells in culture possess functional EPO-Rs
stimulated significantly and dose dependently. This pro- through which EPO can elicit mitogenic and possibly
liferative response was smaller but also evident 24 hours other cytokine actions. We are currently investigating
after EPO addition. The addition of 10% NCS to quies- how these initial in vitro observations may apply to the
biology of the normal and diseased kidney.cent MCTs served as the positive control.
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Fig. 5. EPO-R transcripts in control cells.
(A) Human cells. In OCIM 1 cells (positive
control), all three EPO-R PCR products are
detected (lanes 3 through 5, 372, 104, 240 bp).
Lane 1 shows a DNA ladder and lane 2 the
b-actin signal. In HeLa cells (negative con-
trol), no EPO-R message (lane 7, 240 bp) is
detected. Lane 6 represents b-actin message.
(B) Mouse cells. In HCD 57 cells (positive
control), two EPO-R PCR products are shown
(lanes 3 and 4, 219 bp, 118 bp). In NIH
3T3 cells (negative control), corresponding
EPO-R message is not detected (lanes 6 and
7). Lane 1 shows DNA ladder, and lanes 2
and 5 show b-actin from respective cell lines.
Given our findings, one would expect that clinically whether EPO’s proliferative actions do, in fact, stimulate
cystogenesis in this condition. Finally, a small percentageoccurring or experimentally induced alterations in renal
EPO production per se would result in detectable of patients with renal cell carcinoma produces increased
amounts of EPO [36]. Preliminary data from our labora-changes in renal structure and function. Chronic anemias
that are not caused by sickle cell disease or other hemo- tory demonstrate that EPO stimulates mitogenesis in
human and rat renal carcinoma cell lines, raising thelytic disorders have not been reported to cause significant
anatomical or functional changes in the kidney [31]. This concern that the administration of EPO for the treatment
of anemia could conceivably hasten the growth of somemay indicate that elevated EPO levels cause down-regu-
lation of EPO-R expression in the kidney or that the renal malignancies.
Only one study published to date has shown that EPOtrophic effects of EPO are suppressed by counteracting
factors or that renal histology and function in such condi- treatment of rats with cis-platinum–induced acute renal
failure enhances functional recovery [37]. Because mosttions have not been specifically examined. Severe, more
acute anemia induced in rats was shown to lead to sig- forms of acute renal failure caused by acute tubular ne-
crosis are associated with a transient depression of renalnificant injury in S1 segments of proximal tubular cells
and additional morphological changes in the interstitium EPO synthesis [38–40], EPO replacement may thus serve
to hasten the repair of the injured kidney.of the cortical labyrinth [32]. Whether the associated
sharp increase in EPO production influenced the ob- Recent work on the biological functions of EPO in
nonerythroid cells has demonstrated that vascular endo-served histologic picture or renal function in this study
is not known. thelial cells express EPO-Rs and that EPO acts in these
as a mitogen and a motogen [9, 10], as vasoconstrictorAcquired renal cysts may be another condition in
which EPO’s renotrophic effects could be significant. and activator of angiogenesis, in part via induction of
endothelin-1 [41, 42]. We reported that incubation ofAlthough cyst fluid is often found to contain increased
levels of EPO [33], it is unknown whether cyst growth vascular endothelial cells with EPO causes significant
changes in the expression of immediate early responseis, at least in part, the result of EPO’s growth-promoting
capability or whether the latter contributes to the in- genes (c-jun, c-myc) and the genes of several vasoactive
peptides (atrial, brain, and C-type natriuretic peptide,creased incidence of renal cell carcinomas noted in these
patients. Similarly, a significant percentage of patients and endothelin-1) [43]. These findings reconfirm the abil-
ity of vascular endothelial EPO-Rs to transmit mitogenicwith autosomal dominant polycystic kidney disease and
end-stage renal failure has relatively normal EPO and and other transactivating signals. It was recently reported
that EPO increases Ca21 influx in glomerular mesangialhematocrit levels [34], and renal cyst fluid has also been
found to be rich in EPO [35]. Again, it is unexplored cells [17], a response previously observed in vascular
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Fig. 6. Specific 125I-EPO binding in murine
proximal tubular cells (MCTs). (A) Equilib-
rium binding curve and Scatchard plot (insert)
of 125I-rhEPO binding in MCTs (means 6 se).
Apparent Kd, derived by Scatchard or nonlin-
ear analysis, was 96.1 6 6.1 pm (N 5 3), and
Bmax was 0.3 6 0.07 fmol/mg protein; there was
only a single class of high-affinity receptors.
(B) Time dependence of total ( ), nonspecific
(n), and specific 125I-EPO binding (d) to
MCTs (means 6 se). Binding, assessed at 0.25,
0.5, 1, 2, 3, and 4 hours, reached a plateau at
approximately 2 hours.
smooth muscle cells [44]. This response occurs via an highest in MCTs (Kd approximately 96 pm), intermediate
in HCTs (Kd approximately 1.1 nm), and low in HMCDsEPO-R–operated Ca21 channel, which, in turn, is acti-
vated by tyrosine phosphorylation of phospholipase (Kd approximately 1.3 nm). Serum levels of EPO under
nonanemic and nonhypoxic conditions are between 5C-g1. This mechanism may be an additional explanation
for the ability of EPO to generate clinical hypertension. and 35 mU/ml, that is, in the low picomolar range [1].
These concentrations are well below the Kd values weIn neuronal cells, EPO-Rs have been located and were
found to increase intracellular calcium and protect identified in cultured renal cells. Although not known,
it appears conceivable that EPO concentrations in theagainst glutamate neurotoxicity [12, 13, 16, 45]. It ap-
pears that some of the in vitro functions of EPO in Leydig interstitium of the renal cortical labyrinth, that is, in
the immediate vicinity of EPO secreting and adjacentcells, placental endothelial cells, and gastric epithelial
cells are also found in vivo [11, 14, 15]. tubular cells exceed those seen in the periphery. These
higher local concentrations of EPO may, in turn, beSpecific binding of EPO to cultured renal cells oc-
curred to a single class of receptors and with relatively sufficient to activate EPO-Rs in vivo. Furthermore, am-
bient EPO concentrations in the kidney can be dramati-low Bmax values, a pattern also found in erythroid progeni-
tor and other nonerythroid cells [8]. Binding affinity was cally increased by tissue hypoxia or the administration
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Fig. 7. Immunodetection of EPO-R protein in MCTs. (A) Western blots of immunoprecipitated MCT membrane protein. Lane 1 shows two
EPO-R immunoreactive bands of approximate molecular mass of 68 and 90 kDa, respectively. Lane 2 demonstrates that preincubation of anti-
EPO-R antibody with excess EPO-R antigen prevents the detection of EPO-R proteins, confirming immunospecificity of the anti-EPO-R antibody.
Lane 3 shows molecular weight markers. (B) Western blots of immunoprecipitated mouse spleen cell membrane protein. Lane 2 depicts two
immunoreactive bands of approximate molecular mass of 68 and 90 kDa, respectively. These were obtained from anemic animals. Lane 1 shows
corresponding data from nonanemic mouse spleen. In these, no 68 kDa protein was detected, whereas the 90 kDa band remained detectable, thus
suggesting that the smaller protein represents the EPO-R. Lane 3 shows molecular weight markers.
of recombinant EPO [1]. Under these circumstances, spleen was also found in HCD 57 cells (not shown). This
moiety of EPO-R has been previously described in theeven if EPO-R–binding affinities and surface expression
were as low as those found in this in vitro study, EPO-R latter cells [22], strongly suggesting that MCTs express
this receptor protein as well. The fact that experimentalactivation could occur. An additional factor in this regard
may be the surface distribution of EPO-Rs. Renal tubu- anemia induced the expression of the 68 kDa protein,
whereas it only modestly affected that of the 90 kDalar cells, distinct from erythroid progenitor cells, grow
in polarized monolayers. A large number of hormone protein, supports the notion that the former is likely the
EPO-R. The exact nature of the 90 kDa protein requiresand cytokine receptors in tubular cells are concentrated
on their basolateral side [46]. If EPO-Rs in tubular cells additional investigation.
The mitogenic response elicited by EPO was dosewere likewise preferentially expressed in a basolateral
distribution, their endocrine or paracrine stimulation in dependent and specific. It was, not unexpectedly, less in
magnitude than that elicited by 10% NCS (Fig. 8) andvivo would be facilitated, whereas in vitro activation may
be difficult. Under the latter culture conditions, apically became most prominent after 48 hours of incubation, a
pattern also observed when MCTs are stimulated withadded EPO may not reach basolaterally located EPO-Rs
in concentrations sufficient to initiate a physiologic re- other growth factors [20]. Although it remains to be
proven, it is conceivable that EPO stimulates mitogenesissponse. These possibilities await investigation. Finally, the
as yet undefined expression pattern and ligand-binding in renal cells not only through its own receptor but
also via as yet unidentified mediators or pathways. Suchkinetics of the EPO-R in the kidney, whether regulated,
constitutive, or altered by pathologic conditions, are ex- indirect action has recently been reported in vascular
endothelial cells, in which EPO stimulates angiogenesis,pected to modify biological responses to EPO further.
We detected in murine proximal tubular cells two at least in part, via induction of endothelin-1 synthesis
[41, 42].EPO-R immunoreactive proteins of approximately 68
and 90 kDa, respectively (Fig. 7). The cloned murine It is of note that cells of the neuronal type express
EPO-Rs on their surface but fail to undergo mitosis whenEPO-R cDNA encodes a 55 kDa polypeptide, and the
EPO-R is post-translationally modified by N-linked gly- exposed to EPO [12]. Vascular endothelial and gastric
mucosal cells, by contrast, proliferate when exposed tocosylation and phosphorylation, increasing its mass to
78 kDa and above [47, 48]. The 68 kDa protein that EPO through mitogenic signals transmitted by its recep-
tor, as well as through induction of endothelin-1 synthesiswe consistently detected in MCTs and in anemic mouse
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in the former [9, 10, 15, 40, 41]. Although we show that
EPO acts as a mitogen in renal cells, it is very unlikely
that renal cells depend exclusively on EPO for their in
vitro or in vivo growth or survival. Erythroid progenitor
cells, at certain stages, depend for growth and survival
on EPO and in addition on interleukin-3, insulin-like
growth factor-I, stem cell factor, and other cytokines [1,
8, 49]. Some of the same growth factors, for example,
insulin-like growth factor-I, but also epidermal growth
factor and hepatocyte growth factor, act as mitogens and
survival factors when the kidney is injured as in acute
tubular necrosis [50]. Following toxic or ischemic tubular
injury, adaptive increases in cytokine or cytokine re-
ceptor expression or the administration of renotrophic
growth factors appear to aid the tubular repair process
by stimulating cell proliferation and inhibiting apoptosis
[50]. It is conceivable that EPO elicits analogous effects
in acute tubular necrosis, as was suggested by Vaziri,
Zhou and Liao [37].
In summary, we have shown that cortex, medulla, and
papilla of both human and rat kidney express species-
specific EPO-R mRNAs. More specifically, authentic
EPO-R transcripts are expressed in HCTs and MCTs,
HMCs, RMCs, and HMCDs. EPO binding occurs to a
single class of receptors. EPO-R protein has been identi-
fied in mouse proximal tubular cells, and in these, EPO
stimulates DNA synthesis and cell proliferation. In con-
clusion, our data show that EPO acts in vitro as a reno-
tropic mitogen and that the expression of authentic
EPO-R, a member of the cytokine receptor superfamily
[51], in renal tubular and mesangial cells and in kidney
cortex, medulla, and papilla has allowed us to identify the
critical system through which endocrine and paracrine
actions of EPO may be elicited. Although its functions
in vivo remain to be identified, EPO may play a role in
renal development, cell survival, cell proliferation, cell
migration, and differentiation.
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